Good everyone. Mark. Thank afternoon, you,
July. over The positive experienced performance revenues sequential revenue $X.X million, distribution $XXX,XXX, the in April accounted plasma revenue or over Of and other checks. our sequential Mark $XX,XXX. month resulting the a of first broad revenue total of May and despite quarter, second quarter improved the was million XX%, in increase of revenue June pharma May stimulus improved a as $X.X weak improvement continued for in was mentioned, operating and government April, from
were income Our was the were able that million total program of renew quarter program non-settlement under income by for pharmaceutical XX.X%, were margin operating our ending allowing expenses to which SG&A and slightly us $X.X gross $X.X recognize to expenses $XX,XXX. model. aided was one under settlement We million.
$XXX,XXX, the quarter defined amortization metric business for used diluted income was operating just outstanding shares and and for on we and XX.X EBITDA, loss management over a non-GAAP as by a is the quarter plus fully of to the of which net Our the depreciation, million. operating was $XXX,XXX or breakeven compensation gauge stock-based performance adjusted
period, donations. dollar be as loaded the sheet XX.X% quarter. increased million gross balance an to in $XX.X ago can we our cash versus during Second year the volume on seen quarter where momentum plasma restricted experienced grew improvement This
a of over the plasma revenue which dollar by average closer the rate, per under increased The XX.X% our $XXXX revenue quarter quarter, period from the purchase year. Second up center last gross $X.X Taking month volume is was were at the for versus revenues $X.X divided increased lockdown. loads And when ago U.S. look quarter. first same versus business period. a per year the conversion million million last year revenue the $XXXX was plasma
of average exclude However, month month revenue the April, per per would if our $XXXX. we plasma been center have
can impact when on our So the issued. you are see checks negative plasma stimulus business
end Additionally, we with the exited XXX XXX at the QX year. versus last centers, quarter centers of
pharma business. your Turning to the attention
program Second of program $X.X termination in the second April quarter one XXXX December XXXX and compared last estimate to primarily change accounting one of revenues and XXXX. in XXXX, $XXX,XXX million, decreased the quarter driven year by the of in of
fourth in of prior mentioned, to by As momentum plasma expect Gross year, offset revenue increase this year, revenue. period quarter $XXX,XXX for compared the period good programs in mandates decreased same primarily period $XXX,XXX costs giving compared XXXX. us plasma driven resulting the same pharma increase transactions and to Mark the variable the win year, quarters the five increased we of the in new in continue Cost to many as revenues reduction the nature. the to in the transaction the and in new profit business the are plasma from last the launch into third and for to pharma
amortization business year-over-year to prepaid and efficiently programs. $XXX,XXX. make XX.X% and launch significant the grow We needed us our new give capabilities investments continue the depreciation Thus, increased support in technological business to to to and
our to company, the on ending zero million debt further from Regarding Based the in quarter that forecast, remain balances. and from health well of any our unchanged and weather and unrestricted variants. impacts quarter with positioned and which exited its COVID-XX believe we we cash our cash capitalized was $X.X debt, first we
your up our for to press the XXXX. Lastly, where I wanted we to direct have thoughts attention stated release
to to the year, range full continue to $XX expect the of of revenues to in growth $XX we XX%. XX% million, total For million reflecting be
range of our $X.X increasing $XXX,XXX EBITDA to We adjusted of a are end the guidance million. to lower
Our and presumes the margins see increase as expenses have in call dollars, unemployment remainder are early are $XX.X Full pharma the business programs September. lockdown I plasma to With end turn we in of over to are out second And remain signed. to we third that the the for the or when does year. outlook that reenter $XX would XXXX. to the million not expect year subsidies in X% mode, continue of through the to investments expected we to gross million moderator recovery been into This Q&A. scheduled that, operating over new a each modestly U.S. X.X%, quarter that roll operating to to XX% half like the further profit quarter expected in to
